1. Use of a therapeutically effective amount of at least one of cystamine analogue or its pharmaceutically acceptable salts for varying the flow of Parkinsons disease in a patient, wherein the analog cystamine, or a pharmaceutically acceptable salt thereof is used as an emergency or neuroprotective neyrovosstanavlivayuschego sredstva.2. Use according to Claim. 1 to reduce the severity of symptoms not related to motor activity, in a patient suffering from a disease Parkinsona.3. Use according to Claim. 1 to attenuate clinical development process zabolevaniya.4. Use according to Claim. 1 to slow clinical development zabolevaniya.5. Use according to Claim. 1, characterized in that the patient is in an early stage of development Parkinsona.6 disease. Use according to Claim. 1, characterized in that the patient is in stage III, in accordance with the classification of Hoehn and Yahr (Hoehn and Yahr) .7. Use according to claim 1, characterized in that a therapeutically effective amount of at least one of cystamine analogue or a pharmaceutically acceptable salt thereof is from about 0.1 to about 750 mg / kg body weight per den.8. Use according to Claim. 1, characterized in that a therapeutically effective amount of at least one of cystamine analogue or a pharmaceutically acceptable salt thereof may be used as a finished dosage form containing from 6 to 2000 mg of active ingredienta.9. A combination of at least one cysteine and cystamine analogue or pharmaceutically acceptable salts to alter the course of disease Parkinsona.10. Combination according to item 9, wherein the analog of cysteamine and cysteine present in a ratio of 10: 1 to 1:10 by an1. Использование терапевтически эффективного количества как минимум одного аналога цистамина или его фармацевтически приемлемой соли для изменения течения болезни Паркинсона у пациента, где аналог цистамина или его фармацевтически приемлемая соль используется в качестве экстренного нейрозащитного или нейровосстанавливающего сред
